CD276 and pancreatic neoplasm: Ongoing exploration of novel or optimized targets includes B7-H3 and GD2 for brain cancer, MSLN and CEA for pancreatic cancer, MSLN and FAP for mesothelioma, and GPC3 for liver cancer.